Menu
Menu
Genomics is changing how we understand cancer
The next chapter is about turning insight into action.
Precision oncology is entering a new era.
As next-generation sequencing, liquid biopsy and advanced genomic technologies continue to evolve, the opportunity is no longer simply to generate more data — but to translate increasingly complex genomic information into clinically meaningful insights.
Insights that can help us:
Join SOPHiA GENETICS for an evening of expert discussion exploring the next chapter in precision oncology — where genomic data, clinical expertise and innovation converge to bring precision medicine closer to the patient.
DR. KOJO S. ELENITOBA-JOHNSON, MD
Chair, Department of Pathology and Laboratory Medicine
Memorial Sloan Kettering Cancer Center
Dr. Kojo S. Elenitoba-Johnson is a physician-scientist specialising in hematopathology and molecular genetic pathology, with more than three decades of experience in pathology and molecular pathology.
His work focuses on genomic and proteomic alterations in lymphoma and their diagnostic and therapeutic applications, including the use of advanced genomic approaches such as next-generation sequencing in hematologic malignancies.
DR. OMShree
Scientific Officer, Molecular Diagnostics & Translational Medicine
Tata Memorial Centre
Dr. Omshree brings a clinical and translational perspective from Tata Memorial Centre, one of India's leading institutions in cancer care, research and education.
Her work contributes to the evolving role of molecular diagnostics and genomic medicine in cancer, and how advances in genomics can translate into meaningful clinical practice and patient care.
DR. SRIDHAR SIVASUBBU
Chief Diagnostics & Research Officer & Lab Director
Karkinos Healthcare
Dr. Sridhar Sivasubbu brings extensive expertise across genomics, molecular diagnostics and precision medicine, with a strong focus on translating genomic science into healthcare.
At Karkinos Healthcare, his work sits at the intersection of diagnostics, research and cancer genomics. He has also been involved in initiatives such as the Bharat Cancer Genome Atlas, supporting the development of genomic resources to advance cancer research and more personalised approaches to cancer care in India.
13 October 2026 | 3:00 PM | Prince Court Medical Centre (PCMC), Kuala Lumpur
Join leading voices from across Malaysia’s healthcare and oncology community for an afternoon exploring how precision oncology can move from vision to clinical impact.
Hear perspectives from IHH, the Ministry of Health, SOPHiA GENETICS and leading clinicians on the evolution of precision oncology in Malaysia — from genomic insights and AI-powered innovation to real-world clinical practice.
A Milestone for Precision Oncology
A key highlight of the afternoon will be the Memorandum of Understanding signing between Premier Integrated Labs (PIL) and SOPHiA GENETICS, marking a shared commitment to advancing precision medicine and strengthening Malaysia’s precision oncology ecosystem.
The programme will also feature clinical cases, expert perspectives and opportunities to connect with colleagues shaping the future of cancer care.
Programme
| Session | Activity |
|---|---|
| Opening | Shaping the Future of Precision Oncology in Malaysia |
| IHH Keynote | IHH’s Vision for Precision Oncology and the Future of Cancer Care |
| MOH | Malaysia’s Precision Oncology Journey: From Vision to Access |
| SOPHiA GENETICS | AI-Powered Precision Oncology: From Genomic Data to Clinical Impact |
| MOU Signing | PIL × SOPHiA GENETICS: A Partnership for the Future of Precision Oncology |
| Clinical Cases | Precision Oncology in Practice: From Genomic Insights to Patient Care |
| Networking | Building the Precision Oncology Ecosystem in Malaysia |
Register your Interest
We would be delighted to have you join us for this important milestone in Malaysia’s precision oncology journey.
El próximo 15 de octubre, en las instalaciones de INMEGEN, se llevará a cabo el GENOMiCS INSIGHTS Day México, un encuentro que reunirá a líderes clínicos, investigadores y especialistas en genómica para compartir experiencias y discutir el papel creciente de la medicina de precisión en la atención de pacientes oncológicos.
Durante la jornada se abordarán temas clave como los avances en programas de prevención y vigilancia genómica, la evolución del perfilamiento molecular desde tejido hasta biopsia líquida, y la implementación de programas de secuenciación a gran escala en instituciones de referencia internacionales. Asimismo, se presentarán experiencias regionales sobre el uso de la biopsia líquida para apoyar la toma de decisiones terapéuticas en cáncer y casos reales de adopción de tecnologías genómicas en la práctica clínica.
El evento contará con ponentes de reconocidas instituciones de México, Estados Unidos y Brasil, quienes compartirán perspectivas clínicas, operativas y científicas sobre la integración de la genómica en los sistemas de salud. La jornada finalizará con una mesa redonda y un espacio de networking, promoviendo el intercambio de conocimientos y la colaboración entre los profesionales de la región.
What: SOPHiA GENETICS exclusive networking event
Date: 15 de octobre
Time: 8h:30-13h:30
Where: INMEGEN
8:30 – 09:00
Registration
9:00 – 09:15
Opening
9:15 – 9:45
Cuando la genómica se convierte en prevención.
Avances y resultados de la Estrategia de Vigilancia Anticipada EVA
Carmen Alaez, MSc, PhD.
Head of Genomic Diagnostics Department
INMEGEN, México
9:45 – 10:30
From Tissue to Blood: The Evolution and Spectrum of Precision Profiling at MSK
Anita Bowman, MSc
Associate Director - Clinical Bioinformatics
Memorial Sloan Kettering Cancer Center, USA
10:30 – 11:00
Coffee Break
11:00 - 11:20
Implementation of the MSK-ACCESS test at a reference oncology hospital in Brazil
Mariana Vargas Cruz, MSc, PhD
Scientific Advisor
Hospital Sírio-Libanês, Brazil
11:20 – 11:40
Biopsia líquida: del biomarcador a la decisión terapéutica en cáncer de próstata y pulmón
Melania Abreu, MD
Clinical Geneticist
Genos Médica, México
11:40 - 12:30
Roundtable
12:30 – 13:30
Refreshements and Networking
Conozca cómo SOPHiA DDM™ permite realizar análisis precisos en diversas áreas de la medicina, desde oncología hasta enfermedades raras.
Participe en una conversación sobre el futuro de las instituciones de salud e investigación y descubra cómo aprovechar el potencial de los datos de secuenciación de nueva generación (NGS) para generar resultados rápidos, sólidos y accionables que faciliten una toma de decisiones informada.
Interactúe con colegas, investigadores y usuarios de la plataforma SOPHiA DDM™ en un espacio diseñado para el intercambio de conocimientos, experiencias y oportunidades de colaboración científica.
Le invitamos a participar en el exclusivo GENOMiCS INSIGHTS DAY Uruguay, que se llevará a cabo el próximo 22 de octubre en el Radisson Hotel.
El evento contará con la participación de especialistas y clientes que compartirán su experiencia real en la práctica clínica, abordando temas de alto impacto: desde la aplicación del NGS en oncología y hematología hasta el panorama actual del cáncer hereditario en Latinoamérica.
La jornada reunirá experiencias concretas de clientes que utilizan la plataforma SOPHiA DDM™ en su día a día, ofreciendo una perspectiva directa sobre su impacto en el diagnóstico molecular y la toma de decisiones clínicas. El evento culminará con una mesa redonda y un espacio de cocktails y networking, ideal para el intercambio de conocimientos y oportunidades de colaboración.
A continuación, encontrará la agenda preliminar del evento
What: SOPHiA GENETICS exclusive networking event
Date: 22 de octobre
Time: 19h:00-22h:00
Where: Radisson Hotel
19:00 – 19:30
Una Red Global de Inteligencia Genómica:
Presentamos SOPHiA GENETICS
Daniel Acevedo
Sales executive, South LATAM
SOPHiA GENETICS
19:30 – 20:00
Genómica aplicada a la hematología: experiencia del Hospital de Clínicas con paneles SOPHiA GENETICS
Sofía Grille, MD, PhD.
Profesora Titular y Directora de la Unidad Académica de Hematología, Hospital de Clínicas, Universidad de la República, Uruguay
20:00 – 20:30
NGS en la práctica oncológica: experiencia del Hospital Maciel en cáncer de pulmón y colorrectal.
Juan Martín Marques, PhD.
Director Científico del Laboratorio de Oncología Molecular del Hospital Maciel. Líder de Servicios de NGS, Laboratorio de Biología Molecular del Sanatorio Americano , Uruguay
20:30 - 21:00
Rastreando el Cáncer: Del Riesgo Hereditario a la Detección en Tiempo Real
Bruno Piovezan, Msc.
Subject Matter Expert LATAM
SOPHiA GENETICS
21:00 – 21:30
Sesión de Mesa Redonda
21:30 – 22:00
Cocktails & Networking
Conozca cómo SOPHiA DDM™ permite realizar análisis precisos en diversas áreas de la medicina, desde oncología hasta enfermedades raras.
Participe en una conversación sobre el futuro de las instituciones de salud e investigación y descubra cómo aprovechar el potencial de los datos de secuenciación de nueva generación (NGS) para generar resultados rápidos, sólidos y accionables que faciliten una toma de decisiones informada.
Interactúe con colegas, investigadores y usuarios de la plataforma SOPHiA DDM™ en un espacio diseñado para el intercambio de conocimientos, experiencias y oportunidades de colaboración científica.
📍 National Institutes of Health (NIH), Kuala Lumpur, Malaysia | ⏱️ 2-hour session (10am - 12pm) | 8 October 2026
An exclusive educational session for government laboratory specialists, bioinformaticians, and pathologists
About This Session
As genomic testing volumes continue to rise across public healthcare systems, laboratories are under increasing pressure to deliver faster, more consistent, and more clinically actionable results.
SOPHiA GENETICS, in partnership with Science Vision, invites government stakeholders at the forefront of genomic diagnostics in Malaysia to a dedicated educational session, offering a substantive discussion of the analytical and interpretive challenges facing genomic laboratories today, and how AI-powered platforms such as SOPHiA DDM™ are helping address them.
Participants will gain practical insight into modern genomic workflows, observe the platform in a live demonstration, and have the opportunity to contribute their own laboratory's challenges to the discussion.
Why Attend
Agenda
| Agenda |
|---|
| Welcome & Stakeholder Introductions |
| How SOPHiA DDM™ Tackles Real-World Genomic Challenges |
| Live Platform Demo — See SOPHiA DDM™ in action, from sample to report |
| User Experience Sharing |
| Open Discussion & Q&A |
Who Should Attend
Government laboratory specialists, bioinformaticians, pathologists, and public healthcare stakeholders involved in genomic testing and analysis.
Join us at the 2026 ASHG Annual Meeting in Montreal to explore how SOPHiA DDM™ supports genomic analysis and interpretation across rare and inherited disorders, including hereditary cancer, and pharmacogenomics.
Visit us at Booth #517 to connect with our genomics experts, experience SOPHiA DDM™ firsthand and discover how a data driven approach can help laboratories streamline complex genomic workflows and turn data into meaningful insights.
More ways to connect with us at ASHG
Join us at our CoLab
Hear about Trillium Health Partners’ approach to PMS2/PMS2CL disambiguation and see the latest data for our enhanced exome solutions.
Friday, October 23 | 10.15-10.45 | CoLab Theatre 2
Explore our poster presentation
Comprehensive detection of SNVs / Indels, CNVs and complex gene conversions across germline applications using an enhanced exome approach
Authors: Tamara Maas, Yuanlong Liu, Bita Khalili, Dmitri Ivanov, Alfredo Mari, Jian Yu, Rieke Kempfer, Zhenyu Xu
Wednesday, October 21, 2:30-4:30 EDT
Discover new data and insights from our latest work.
Plan your ASHG visit
Whether you're working on rare disorders, hereditary cancer, or pharmacogenomics, we'd love to connect and learn more about the challenges your laboratory is working to solve.
Meeting slots at ASHG fill quickly. Book time with our team before you arrive in Montreal.
See you there. 🧬
Join SOPHiA GENETICS at SFMPP 2026 in Paris, France! Come meet our team of experts at Booth #16. We are looking forward to discussing how we support laboratories and healthcare institutions with scalable, data-driven solutions. Check out our full program below:
The SOPHiA GENETICS team will be happy to see you join our Flash Symposium on Friday, 9 October from 12:35-12:50PM in the PLÉNIÈRE Room.
“Optimisation des flux d’analyse NGS en oncologie solide : retour d’expérience d’un service de Pathologie”
Speakers:
In this session, Benjamin will share how his team is optimizing NGS analysis workflows in solid tumor oncology, covering the challenges of implementing NGS in routine clinical practice and the impact on turnaround time and workflow efficiency.
SOPHiA GENETICS is proud to join the 37th CBGM in São Luís, Maranhão (Sept 2–5, 2026), celebrating 40 years of SBGM and the future of precision medicine in Brazil. Meet us at Booth #20 to discover the latest innovations of the New Generation SOPHiA DDM™ Platform, with a special focus on Exome advancements.
Join our BioPharma team to discover how AI-powered technology and diagnostics are helping advance precision oncology.
We are excited to join the 26th ACGH Congress — Asociación Colombiana de Genética Humana, taking place August 13–15 in Pereira, Colombia. Join us and meet our LATAM team to learn how SOPHiA DDM™ helps clinical genetics laboratories across the region implement optimized, technology-agnostic genomic testing — from exome design to actionable diagnosis.
The SOPHiA GENETICS team is looking forward to seeing you at our sponsored academic breakfast talk.
Academic Breakfast Talk on Friday, August 14th, from 8:00 to 9:00 am — Salón 1, Genética Médica.
"From Design to Diagnosis: Implementation of Optimized Exomes in Clinical Practice"
Luna Rodríguez, MSc., Subject Matter Expert, SOPHiA GENETICS
Dr. Coztli Ocelotl Azotla, Geneticist, Genos Médica
In this talk, we will explore how optimized exome design is reshaping clinical genetics workflows across Latin America, bridging the gap between test design and real-world diagnostic impact.
Come find us at booth #19 for expert discussions and collaborative opportunities.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.